Navigation Links
Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
Date:9/24/2008

, Arpida has an innovative antifungal therapy (TLT) which is in Phase III clinical trials in Europe, targeting onychomycosis.

Moreover, the company has several other leads in optimisation and additional discovery programmes derived from its own discovery platform at various research stages.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

Contacts:

Dr Jurgen Raths, President and CEO,

Tel.: +41-61-417-96-60;

Harry Welten, MBA, CFO and Senior Vice President,

Tel.: +41-61-417-96-65;

Paul Verbraeken, Head of Corporate Communications,

Tel.: +41-61-417-96-83


'/>"/>
SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arpida Invited to Present Data on Iclaprim at Scientific Conference
2. Arpida Provides Further Comments on the Pivotal Phase III Trials
3. Arpida Enrols First Patients in "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
10. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
11. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 2014 Research and Markets ... Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and Geography) ... to their offering. A new ... geography) - Size, Share, Global Trends, Company Profiles, ... Forecast, 2013 - 2020", suggests that the global ...
(Date:8/20/2014)... Research and Markets  has announced the addition ... to their offering. Global Market Report of ... globally and regionally ( Europe , ... Latin America etc.). It captures Pralmorelin market ... focuses on three primary areas; manufacture methods & technology development, ...
(Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com ... available in its catalogue: Global Coatings ... http://www.reportlinker.com/p01375204/Global-Coatings-for-Medical-Devices-Industry.html This report analyzes ... in US$ Million by the following Product Segments: ... Coatings. The report provides separate comprehensive analytics for ...
Breaking Medicine Technology:Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and Geography) - Research Report, 2013 - 2020 2Global Market Report of Pralmorelin 2Global Coatings for Medical Devices Industry 2Global Coatings for Medical Devices Industry 3Global Coatings for Medical Devices Industry 4Global Coatings for Medical Devices Industry 5Global Coatings for Medical Devices Industry 6Global Coatings for Medical Devices Industry 7Global Coatings for Medical Devices Industry 8Global Coatings for Medical Devices Industry 9Global Coatings for Medical Devices Industry 10Global Coatings for Medical Devices Industry 11Global Coatings for Medical Devices Industry 12Global Coatings for Medical Devices Industry 13Global Coatings for Medical Devices Industry 14Global Coatings for Medical Devices Industry 15Global Coatings for Medical Devices Industry 16Global Coatings for Medical Devices Industry 17Global Coatings for Medical Devices Industry 18Global Coatings for Medical Devices Industry 19Global Coatings for Medical Devices Industry 20Global Coatings for Medical Devices Industry 21
... Pa., Aug. 22, 2011 Cephalon, Inc. (Nasdaq: ... of its 2.50 percent Convertible Senior Subordinated Notes due ... Subordinated Notes due 2015 (the "2015 Notes") in respect ... with a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd., ...
... Aug. 22, 2011 Clinigene International Limited, ... Phase I-IV Clinical Research Organization, and Spaulding ... Cardiac Core Lab, and Medical Device Manufacturer, ... establishes a reliable, trustworthy, and cost-efficient global ...
Cached Medicine Technology:Cephalon Gives Notice of Anticipated Fundamental Change to Holders of Its 2.50% Convertible Senior Subordinated Notes due 2014 and 2.00% Convertible Senior Subordinated Notes due 2015 2Cephalon Gives Notice of Anticipated Fundamental Change to Holders of Its 2.50% Convertible Senior Subordinated Notes due 2014 and 2.00% Convertible Senior Subordinated Notes due 2015 3Cephalon Gives Notice of Anticipated Fundamental Change to Holders of Its 2.50% Convertible Senior Subordinated Notes due 2014 and 2.00% Convertible Senior Subordinated Notes due 2015 4Cephalon Gives Notice of Anticipated Fundamental Change to Holders of Its 2.50% Convertible Senior Subordinated Notes due 2014 and 2.00% Convertible Senior Subordinated Notes due 2015 5Spaulding Clinical Announces Strategic Partnership with Clinigene International, India for Providing Comprehensive Early Clinical Solutions to Pharmaceutical and Biotech Clients 2Spaulding Clinical Announces Strategic Partnership with Clinigene International, India for Providing Comprehensive Early Clinical Solutions to Pharmaceutical and Biotech Clients 3
(Date:8/20/2014)... New York, NY (PRWEB) August 20, 2014 ... Open Tennis Championship tickets in NYC. In just a ... USTA Billie Jean King Tennis Center. The event was originally founded ... the 2013 event, Rafael Nadal was forced to withdrawal from the ... of the 2014 women’s tournament and will return to New York ...
(Date:8/20/2014)... in Australia examined patient and tumor characteristics for ... tumor cell growth) in an effort to increase ... , Author: Sarah Shen, M.B.B.S., ... colleagues. , Background: The tumor characteristic known ... been connected with prognosis and survival in melanoma ...
(Date:8/20/2014)... Opinion: The time to deploy Ebola vaccines is now, ... vaccines is now, according to a commentary being published ... Medicine . The authors from Yale School of ... geographic dissemination of the current Ebola outbreak represent a ... under current efforts. Several Ebola vaccines have been developed ...
(Date:8/20/2014)... of brain cells that act as a "sleep switch" ... and staying asleep, a new study suggests. In ... often results in nighttime confusion and wandering, according to ... Rush Memory and Aging Project, which includes nearly 1,000 ... followed until death, at which point their brains are ...
(Date:8/20/2014)... The Board of Directors of top international ... pleased to announce the expansion of its healthcare ... and the surrounding region. In support of this strategic ... has relocated to the firm’s office in Shanghai, China, ... design and to better support regional clients. , ...
Breaking Medicine News(10 mins):Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 2Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 3Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 4Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 5Health News:Patient, tumor characteristics for high-mitotic rate melanoma 2Health News:News from Annals of Internal Medicine 2Health News:Seniors' Sleep Woes May Be Linked to Loss of Brain Cells 2Health News:Perkins Eastman Expands Presence in China 2Health News:Perkins Eastman Expands Presence in China 3
... most common breast cancer uses the most efficient, powerful ... that system kills it, researchers report. This method ... patients, particularly those resistant to standard therapies such as ... Human estrogen receptor-positive breast cancer cells thriving in a ...
... The second generation drug-eluting stent, everolimus-eluting stent ... in randomised controlled trials over the first ... earlier studies comparing EES with another first ... only demonstrated the non-inferiority of EES; the ...
... order to meet future demands for new pharmaceuticals, ... is dependent on the ongoing development of effective ... Because they are so versatile, organometallic molecules are ... reagents containing zinc atoms have certain advantages over ...
... , MONDAY, Aug. 29 (HealthDay News) -- Boxing ... encourage their kids to find sports that don,t focus ... Those are conclusions from the new policy statement from ... Society that recommends that pediatricians vigorously oppose children participating ...
... Meeting & OTO EXPO of the American Academy of Otolaryngology ... of ear, nose, and throat doctors in the world, will ... more than 386 scientific research sessions, 468 posters, and several ... a unique opportunity for journalists from around the world to ...
... 28 (HealthDay News) -- Although it may sound sweet ... behavior, similar to arguing or slinging insults, Canadian scientists ... Queens University in Kingston, Ontario, also revealed that differences ... live, play a role in how aggressive their shouting ...
Cached Medicine News:Health News:Research aims to starve breast cancer cells 2Health News:Clinical outcomes in PCI patients given sirolimus-eluting and everolimus-eluting stents 2Health News:New salts for chemical soups 2Health News:Pediatric Groups Want to KO Boxing for Kids 2Health News:Pediatric Groups Want to KO Boxing for Kids 3Health News:2011 AAO-HNSF poster presentations 2Health News:2011 AAO-HNSF poster presentations 3Health News:2011 AAO-HNSF poster presentations 4Health News:2011 AAO-HNSF poster presentations 5Health News:2011 AAO-HNSF poster presentations 6Health News:2011 AAO-HNSF poster presentations 7Health News:2011 AAO-HNSF poster presentations 8Health News:2011 AAO-HNSF poster presentations 9Health News:2011 AAO-HNSF poster presentations 10Health News:2011 AAO-HNSF poster presentations 11Health News:2011 AAO-HNSF poster presentations 12Health News:2011 AAO-HNSF poster presentations 13Health News:2011 AAO-HNSF poster presentations 14Health News:2011 AAO-HNSF poster presentations 15Health News:2011 AAO-HNSF poster presentations 16Health News:2011 AAO-HNSF poster presentations 17Health News:2011 AAO-HNSF poster presentations 18Health News:2011 AAO-HNSF poster presentations 19Health News:2011 AAO-HNSF poster presentations 20Health News:2011 AAO-HNSF poster presentations 21Health News:Sweet Sparrow Songs May Actually Be Shouting Matches 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: